Abstract: Oxaliplatin is effective for the treatment of advanced colorectal cancer, but its application is restricted because of the doselimiting toxicity. As drug carriers, liposomes are featured with delay release, lesion targeting and they could decrease the side effects of drugs. Active targeting modification of the liposome can change the biological distribution of the anticancer drugs, reduce or reverse multidrug resistance of tumor cells and enhance the effect of antitumor drugs. With these characteristics mentioned above, lipsomes containing oxaliplatin may play an important role in the treatment of colorectal cancer.